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Abstract
Background. Cardiac remodeling in uremia is character-
ized by left ventricular hypertrophy, interstitial fibrosis and
microvascular disease. Cardiovascular disease is the lead-
ing cause of death in uremic patients, but coronary events
alone are not the prevalent cause, sudden death and heart
failure are. We studied the cardiac remodeling in experi-
mental uremia, evaluating the isolated effect of parathyroid
hormone (PTH) and phosphorus.
Methods. Wistar rats were submitted to parathyroidectomy
(PTx) and 5/6 nephrectomy (Nx); they also received
vehicle (V) and PTH at normal (nPTH) or high (hPTH)
doses. They were fed with a poor-phosphorus (pP) or rich-
phosphorus (rP) diet and were divided into the following
groups: ‘Sham’: G1 (V 1 normal-phosphorus diet (np))
and ‘Nx 1 PTx’: G2 (nPTH 1 pP), G3 (nPTH 1 rP),
G4 (hPTH 1 pP) and G5 (hPTH 1 rP). After 8 weeks,
biochemical analysis, myocardium morphometry and arte-
riolar morphological analysis were performed. In addition,
using immunohistochemical analysis, we evaluated angio-
tensin II, a-actin, transforming growth factor-beta (TGF-b)
and nitrotyrosine, as well as fibroblast growth factor-23
(FGF-23), fibroblast growth factor receptor-1 (FGFR-1)
and runt-related transcription factor-2 (Runx-2) expression.
Results. Nx animals presented higher serum creatinine lev-
els as well as arterial hypertension. Higher PTH levels were
associated with myocardial hypertrophy and fibrosis as
well as a higher coronary lesion score. High PTH animals
also presented a higher myocardial expression of TGF-b,
angiotensin II, FGF-23 and nitrotyrosine and a lower expres-
sion of a-actin. Phosphorus overload was associated with
higher serum FGF-23 levels and Runx-2, as well as myo-
cardial hypertrophy. FGFR-1 was positive in the cardiomyo-
cytes of all groups as well as in calcified coronaries of G4
and G5 whereas Runx-2 was positive in G3, G4 and G5.
Conclusion. In uremia, PTH and phosphorus overload are
both independently associated with major changes related
to the cardiac remodeling process, emphasizing the need for
a better control of these factors in chronic kidney disease.
Keywords: FGF-23; hyperphosphatemia; left ventricular hypertrophy;
parathyroid hormone; vascular calcification
Introduction
Cardiovascular disease (CVD) is the leading cause of death
in patients with chronic kidney disease (CKD) in all stages
[1]. Data from the United States (United States Renal Data
System) show that this complication accounts for 42.2% of
17.9 deaths by 100 at-risk patients [2] and sudden death and
congestive heart failure are more frequent than acute my-
ocardial infarction [3].
Pathological cardiac remodeling occurs in response to
injuries such as volume overload and/or arterial pressure
and the myocyte is the principal cardiac cell involved in
remodeling. Left ventricular hypertrophy (LVH) is the re-
sult of early alteration characterized by the hypertrophy of
the myocyte, increased fibrosis and microvascular altera-
tions. Arteriosclerosis and atherosclerosis are closely re-
lated with endothelial dysfunction and acute coronary
events. Atherosclerosis, present in the initial phases of
CKD, is associated with high incidence of calcification of
the coronary arteries, cardiac valves, myocardium and pe-
ripheral arteries [4, 5].
In addition to traditional risk factors to CVD (hyperten-
sion, diabetes, dyslipidemia, smoking, gender, menopause,
advanced age and sedentary lifestyle), patients with CKD
have ‘uremia-related’ risk factors such as anemia, volume
overload and neurohormonal activation, as well as local
factors, inflammation, ischemia, cellular necrosis, apopto-
sis, oxidative stress (OS) and disturbances of the mineral
metabolism [6].
Increased OS has been documented in CKD patients, and
it affects cardiovascular function, increases sympathetic
nervous activity and enhances atherosclerosis primarily
via endothelial cell dysfunction [7]. Nitrotyrosine is one
of the OS markers and is related to cell death, reactive
oxygen species accumulation and endothelial nitric oxide
synthase expression [8].
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Disturbances of the mineral metabolism are early and
frequent in CKD [9]. The progressive loss of renal function
lead to the lower production of calcitriol and phosphorus
retention leading to hypocalcemia, as well as increased
parathyroid hormone (PTH) and fibroblast growth factor
23 [fibroblast growth factor-23 (FGF-23)] secretion. More-
over, recent studies have shown the association of FGF-23
and hyperphosphatemia with left ventricular mass, as well
as with increased mortality in CKD patients [10]. PTH
overload contributes to LVH, myocardial fibrosis and vas-
cular calcification (VC), regardless of arterial pressure [11,
12]. VC is commonly seen in patients with CKD. It has
been shown that high phosphate levels changes the pheno-
type of vascular smooth muscle cells (VSMCs) into calcify-
ing cells with up-regulation of osteochondrogenic markers
like runt-related transcription factor 2 (Runx-2) [13].
In previous studies of experimental uremia in rats, we had
demonstrated that hyperphosphatemia was associated with
myocardial hypertrophy (increased heart weight) and that
high PTH (hPTH) levels induced VC [11, 14]. In this exper-
imental study, we compared uremic parathyroidectomized
groups submitted to diets with different phosphorus content
and different PTH infusion rates. Therefore, the aim of this
study was to evaluate the isolated effect of PTH and phos-
phorus on myocardial tissue and coronary arteries, as well as
to quantify the expression of some proteins involved in these
alterations.
Materials and methods
Experimental protocol
A total of 46 male Wistar rats, at initial weights of 280–320 g, were
obtained from our local breeding colony for use in this 8-week study.
All animals were housed in individual cages in a light-controlled (12 h
on/12 h off) environment in which temperature (25C) and humidity
(25%) were constant. Weight measurement and tail cuff plethysmography
(TCP) were performed weekly.
Some animals were submitted to parathyroidectomy (PTx) and 5/6 neph-
rectomy (Nx), as described below, whereas others were sham operated. All
animals were submitted to implantation of an osmotic minipump for the
infusion of 1–34 rat PTH (Sigma-Aldrich, St Louis, MO) and delivered at a
physiological rate [0.022 lg/100 g/h, normal PTH (nPTH)] or a supraphy-
siological rate (0.11 lg/100 g/h, hPTH) or vehicle (2% cysteine; Sigma-
Aldrich). Immediately after Nx or sham Nx, animals were fed one of three
types of rodent chow (Harlan-Teklad, Indianapolis, IN), identical except for
the phosphorus content, which was 0.2, 0.7 and 1.2%, representing poor,
normal and rich phosphorus content (pP, nP and rP diets, respectively). All
diets were equal in their content of vitamin D, calcium (0.7%), protein
(24%) and calories. A pair feeding protocol was used.
Five subgroups were created:
G1: Sham 1 nP (sham-operated rats fed with nP diet and receiving
infusion of vehicle only)
G2: Nx PTx 1 pP nPTH (nephrectomized rats fed with a pP diet and
receiving nPTH infusion)
G3: Nx PTx1 rP nPTH (nephrectomized rats fed with rP diet and receiv-
ing nPTH infusion)
G4: Nx PTx 1 pP hPTH (nephrectomized rats fed with pP diet and
receiving hPTH infusion)
G5: Nx PTx1 rP hPTH (nephrectomized rats fed with rP diet and receiv-
ing hPTH infusion)
All experimental procedures were conducted in accordance with the
guidelines of the Standing Committee on Animal Research of the Univer-
sity of Sa˜o Paulo.
Surgical procedures. The rats were anesthetized with pentobarbital (50
mg/kg i.p.) and animals of G2, G3, G4 and G5 were then submitted to PTx.
The PTx procedure involved microsurgical techniques using an electrocau-
tery. The animals, including those that were sham operated, were allowed to
recover from surgery for 7 days. Those presenting a serum concentration of
ionized calcium (iCa) <0.9 mmol/L (considered an indicator of successful
PTx) were anesthetized as before and submitted to 5/6 Nx, consisting of
removal of the right kidney and infarction of approximately two-thirds of the
left kidney. The sham-PTx animals were also anesthetized as before and
were then submitted to sham Nx.
PTH infusion. Simultaneous to the Nx procedure, an Alzet model 2mL4
osmotic minipump (Alza Corp., Palo Alto, CA) was implanted subcuta-
neously, providing continuous PTH infusion. On Day 28 (post-Nx), the
animals were given light ether anesthesia and the osmotic minipump
(pumping lifetime, 28 days) was replaced with another minipump set to
the same infusion rate.
Serum sample collection. After 8 weeks of PTH infusion, the animals
were anesthetized and sacrificed through aortic exsanguinations. Serum
samples were frozen at 20C for later biochemical evaluation.
Biochemical evaluation. At Nx procedure, whole blood was collected by
retro-orbital puncture. A model AVL-9140 autoanalyzer (AVL Scientific
Corporation, Roswell, GA) was used to measure iCa levels in this blood
either immediately after collection or following sacrifice (in frozen samples).
Serum creatinine was determined by using a colorimetric assay (modified
Heinegard-Tiderstro¨m). Phosphorus was determined using a different col-
orimetric assay (Labtest, Lagoa Santa, Brazil). PTH was measured using an
immunoradiometric assay kit (Immutopics, San Clemente, CA) and FGF-23
by intact FGF-23 (Elisa assay; Kainos, Japan; reference range 8.2–54.3 pg/
mL); hematocrit was also determined.
Morphological analysis
Myocardial. Hearts were excised, blotted and weighed. We also deter-
mined the heart weight to 100 g of body weight ratio. The hearts were fixed
in buffered formalin.
Cross-sections of the heart, including both ventricles at the equatorial
plane, were embedded in paraffin and cut into 4-lm sections. Tissue
sections were stained with hematoxylin–eosin (HE), Picrosirius red, peri-
odic acid–Schiff (PAS) and Von Kossa. A digital image analysis system
(Leica Imaging Systems Ltd, Cambridge, UK) was used for morphometric
measurements. A pathologist blinded to the origins of the samples per-
formed a qualitative analysis.
To estimate cardiomyocyte hypertrophy, PAS-stained sections were
examined under 3400 magnification. The myocyte diameter (lm) around
oval and central nuclei of longitudinally displayed myocytes was meas-
ured. For each of the following measurements, a total of 10 myocytes per
section of subendocardial region were examined.
Collagen volume fraction (%) was estimated in Picrosirius red-stained
sections under 3200 magnification. Collagen volume fraction was deter-
mined as the percentage of red-stained connective tissue areas per total
myocardial area, excluding perivascular areas. A total of 30 fields per sec-
tion of left ventricle in the special subendocardial region were examined.
Arteries. The wall thickness and wall and lumen area of small intra-
myocardial arteries were determined by planimetry using the automatic
image analyzing system cited before. The contours of the arterial profiles
were marked manually with a cursor and the maximal and minimal diam-
eters, as well as the wall and lumen areas, were calculated. The wall
thickness of these arteries was then determined as the mean of the meas-
urements of the two opposite walls toward the minimal diameter (because
this is the direction where measurements are least affected by sectioning
angle). The wall:lumen ratio was calculated by dividing the mean minimal
diameter by the mean lumen diameter.
Wall thickness of the medium layer: To evaluate the wall thickness
of the medium layer, we used HE-stained sections and selected arteries of
50–200 and 200–400 lm diameters and a minimal and maximal diameter
ratio of >0.5 lm. The images were analyzed under 3580 magnifications
using the software IMAGE J (National Institutes of Health, Bethesda,
MD). Four measures were taken, two of each diameter, minimal and
maximal, and the results were expressed in micrometer.
Evaluation of the arterial wall: To evaluate all the different layers of
arteries in a semi-quantity form, the following scores were used:
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(0) ‘normal’: an intact intima and media layer and without calcifications;
(1) light lesion: partial or total discontinuity of intima/elastic membrane,
organized media layer and without calcifications;
(2) moderate lesion: partial or total discontinuity of intima/elastic mem-
brane, disorganized media layer and without calcifications;
(3) severe lesion: partial or total discontinuity of intima/elastic membrane,
disorganized media layer and calcifications.
About 3–5 arteries per section were analyzed and received a score and
the comparison was done with the mean scores of each animal.
Calcification. The calcification of the arteries was stained in black color
by Von Kossa and analyzed under3200 magnification. The calcifications
were estimated at the ratio of perceptual calculus between the area stained
in black and the total media layer area.
Immunohistochemical analysis. The immunohistochemical analyses
were performed on transversal paraffin sections of the hearts using an
antibody against angiotensin II (Peninsula, Belmont, CA) and a-actin
(Sigma Chemical Co., St Louis, MO) by streptavidin–biotin/alkaline phos-
phatase technique and transforming growth factor-beta (TGF-b) (Santa
Cruz Biotech, Santa Cruz, MN) and nitrotyrosine (Invitrogen, Carlsbad,
CA) by avidin–biotin/peroxidase technique. Heart sections were also
tested for anti-FGF-23 (kindly provided by Genzyme Co.), anti-fibroblast
growth factor receptor-1 (FGFR-1) (SC-121; Santa Cruz Biotech) and anti-
Runx-2 (ab54868; Abcam Inc., MA), using streptavidin–biotin—LSAB
technique (Dako, CA). Negative controls were performed by omitting the
primary antibody.
To evaluate the angiotensin II and TGF-b expression, we utilized a
point count technique, using a microscope with a 100-point ocular con-
nected to a video monitor. We analyzed 25 fields under 3200 magnifica-
tion. The results were expressed in percentage considering the total area.
We evaluated the frequency of positive arteries for nitrotyrosine and FGF-
23 in the cardiac tissue. The a-actin positivity was semi-quantitatively
evaluated using the following scores: (i) absent or light scoring in few
areas of media layer, (ii) moderate scoring in scattered and irregular areas
of media layer and (iii) strong scoring with uniform distribution in media
layer. FGFR-1 and Runx-2 expressions were evaluated in the arteries and
cardiac tissue; however, no quantification was performed.
Statistical analysis
All data are expressed as mean  standard error. Comparisons of the
biochemical parameters among the groups were made using one-way
analysis of variance (ANOVA) and Newman–Keuls post hoc test. A
two-way ANOVA was conducted in order to understand how biochemical,
morphometric and immunohistochemical parameters could be affected by
the following two factors: phosphorus content in the diet and PTH infusion
rate. In the case of a significant interaction of phosphorus content and PTH
infusion, Bonferroni post-test was performed. When no interaction was
observed, data were rearranged and grouped according to the phosphorus
content in the diet and the PTH infusion rate and Student’s t-test analysis
was used. Fisher’s 23 5 exact test was performed to assess the association
between nitrotyrosine and FGF-23 immunohistochemical positivity and
the study groups. GraphPad Prism software, version 4.0 (GraphPad, San
Diego, CA), was employed for all tests except for Fisher’s exact test when
we applied StatXact version 9 (Cytel, Cambridge, MA). Values of P<0.05
were considered to be statistically significant.
Results
TCP, heart weight, biochemical data and hematocrit
Table 1 shows that the arterial pressure and serum creati-
nine were higher in all Nx PTx groups compared to sham
group (P < 0.05). Among Nx PTx groups, G2 showed the
lowest serum creatinine. Heart weight/body weight ratio
was higher in groups with hPTH (G4 and G5) compared
to normal and sham groups (G2, G3 and G1), whereas G3
presented a heart weight higher than G1 and G2. Anemia
was observed in all Nx groups. Nx PTx animals fed a rP diet
developed hypocalcemia and hyperphosphatemia in both
PTH concentrations (G3 and G5). Hypercalcemia was ob-
served in the Nx PTx group with hPTH and fed with pP diet
(G4). As expected, the groups with hPTH infusion showed
the highest PTH serum levels (G4 and G5). Serum FGF-23
was higher in animals with hPTH (G4 and G5) compared to
sham and animals with nPTH fed with pP diet (G2).
Myocardium
Myocardial hypertrophy evaluated through the myocyte
diameter was higher in G3, G4 and G5 groups than in G1
and G2 groups (Table 2). Among the groups with hPTH,
the animals fed with rP (G5) showed the highest myo-
cardial hypertrophy. Myocardial fibrosis was higher in
animals with hPTH and fed with rP (G5) compared to sham
and G2 animals.
The thickness of medium layer was not different among
all the groups (data not shown). The highest artery lesion
score was found in hPTH groups.
Regarding immunohistochemistry findings, only G5
showed an increased expression of TGF-b compared to
sham group. The highest angiotensin II expression was
found in hPTH groups (Table 2). The coronaries of the
animals that received hPTH showed significant expression
of nitrotyrosine (G4 ¼ 32%; G5 ¼ 44%; Figure 1C) and
FGF-23 (G4 ¼ 20%; G5 ¼ 28%; Figure 1D) compared
with the other groups (P < 0.0001) (Figure 1A).
All groups showed positive FGFR-1 expression in my-
ocytes (Figure 2A) and groups that received hPTH infusion
(G4 and G5) presented calcified coronaries, as shown in
Figure 2B. Runx-2 expression was negative in G1 and G2
groups (Figure 3A) but was positive in coronary arteries
and myocytes of the animals from groups G3, G4 and G5
(Figure 3B).
The expression of a-actin was significantly lower in
hPTH groups compared to that of the sham group, giving
a mirror image of coronary lesion score (Figure 4).
Analysis of isolated effects of PTH and phosphorus on
structural, biochemical and immunohistochemical
parameters
Serum creatinine was the only parameter where an interac-
tion between phosphorus and PTH was found. Post-test anal-
ysis disclosed that serum creatinine was influenced by
phosphorus content in the diet (pP ¼ 0.80  0.08; rP ¼
1.02  0.10; P ¼ 0.054).
Table 3 shows the parameters where the interaction be-
tween phosphorus and PTH was not found. Student’s t-test
analysis revealed that hPTH infusion increased TCP, heart
weight, coronary lesion score, myocyte diameter (Figure
5A), fibrosis (Figure 5B) and both TGF-b and angiotensin
II expression (Figure 5C and D, respectively), whereas it
decreased hematocrit and a-actin expression. Regarding
the phosphate content in the diet, the rP groups presented
an increase in serum FGF-23 (Figure 6A) and myocyte
diameter (Figure 6B) and a decrease in hematocrit and ion-
ized calcium. We also observed a tendency to increased
fibrosis and decreased TCP in rP groups.
Parathyroid hormone and phosphorus overload in uremia 3
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Discussion
This study showed that high-serum PTH levels in uremic
animals contributed to myocyte hypertrophy, interstitial
fibrosis and vascular lesion, with a significant change in an-
giotensin II, a-actin, TGF-b, nitrotyrosine and FGF-23 ex-
pression. On the other hand, phosphorus overload contributed
to myocardial hypertrophy and was probably involved in the
myocardial fibrosis event. We also observed an expression of
FGFR-1 in myocytes of all animals and in the coronaries of
those that received hPTH. An interesting finding was the
expression of Runx-2 in coronaries and myocytes of the ani-
mals with phosphorus overload (G3 and G5) and hPTH (G4
and G5).
The past concept that cardiac hypertrophy in uremia is
the result of hypervolemia and hypertension has changed
and currently the involvement of other factors such as ane-
mia, sympathetic overactivity and hyperparathyroidism
have grown in importance [15]. Recently, Siedlecki et al.
[16], in an elegant study, showed that despite the control
of arterial hypertension through the management of renin–
angiotensin–aldosterone system and volume overload,
uremic animals still develop myocardial hypertrophy. In
the current study, all Nx PTx animals showed hyper-
tension and anemia. However, we could evaluate the inde-
pendent contribution of phosphorus and PTH in cardiac
hypertrophy.
It is well known that PTH may contribute to the develop-
ment of myocardial hypertrophy [17]. Clinical studies car-
ried out in patients with secondary hyperparathyroidism and
in general population have demonstrated an association be-
tween PTH serum levels with LVH and mortality [18, 19].
In vitro studies have shown that PTH appears to have
chronotropic, inotropic, as well as hypertrophic effects on
cardiomyocytes [20]. Our results confirm the effect of PTH
in myocardial hypertrophy since the animals that received
hPTH infusion showed increased heart weight and myocyte
diameter.
In uremia, the isolated deleterious effect of hyperphos-
phatemia on cardiac hypertrophy is still a matter of debate.
Our results showed that hyperphosphatemia was associated
with the development of myocardial hypertrophy. We
clearly observed the phosphorus influence when we com-
pared two groups of animals receiving different contents of
phosphorus in the diet (G4 and G5) and that animals fed
with a rP diet presented a higher myocyte diameter. This
finding was similar to that showed by Amann et al. [21],
which demonstrated the protective effect of a pP diet on
the development of myocardial hypertrophy in uremic
animals. However, in the preceding study, the authors
could not rule out the effects of PTH since these animals
also presented lower PTH levels.
Recent studies revealed that phosphorus regulates the
expression of a wide variety of genes involved in the
regulation of enzymes and proteins related to OS [22].
One hypothesis of the deleterious effect of phosphorus
overload would be an indirect action decreasing nuclear
factor erythroid 2-related factor (Nrf2) expression and anti-
oxidant proteins and increasing OS and stimulating hy-
pertrophy as well as myocardial fibrosis. Therefore, thereT
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might be distinct metabolic pathways leading to myocar-
dium changes and VC induced by hyperphosphatemia in
addition to phenotypic changes in VSMCs, which can be
exemplified by the reduction of myocardial hypertrophy
[23], but not of VC, when you reduce phosphorus content
in the diet [24].
Table 2. Myocardium histology and immunohistochemistrya
Myocyte diameter (lm) Fibrosis (%) Coronary lesion score Angiotensin II (%) a-Actin (%) TGF-b (%)
G1—Sham (n ¼ 10) 9.1 6 0.2 1.2 6 0.3 0.4 6 0.1 1.3 6 0.5 2.9 6 0.03 1.1 6 0.2
G2—Nx PTx nPTH pP (n ¼ 8) 9.8 6 0.3 1.7 6 0.5 0.6 6 0.3 1.6 6 0.4 2.7 6 0.1 1.9 6 0.4
G3—Nx PTx nPTH rP (n ¼ 8) 12.5 6 0.3b,c 4.9 6 2.3 0.4 6 0.2 0.7 6 0.2 2.9 6 0.1 2.6 6 0.6
G4—Nx PTx hPTH pP (n ¼ 7) 11.6 6 0.4b,c 5.2 6 1.6 2.1 6 0.2b,d 2.6 6 0.3d 1.9 6 0.3b 3.8 6 0.7
G5—NxP Tx hPTH rP (n ¼ 7) 13.3 6 0.2b,c,e 8.7 6 2.3b,c 2.4 6 0.2b,c,d 2.9 6 0.4b,c,d 2.0 6 0.3b 4.1 6 0.8b
aData are expressed as mean 6 standard error. hPTH ¼ high parathyroid hormone; nPTH ¼ normal parathyroid hormone; Nx ¼ nephrectomized rat;
Sham ¼ control animal.
bP < 0.05 versus G1.
cP < 0.05 versus G2.
dP < 0.05 versus G3.
eP < 0.05 versus G4.
Fig. 1. Nitrotyrosine and FGF-23 immunohistochemical expression in calcified coronaries of animals that received high-PTH infusion. (A) Negative
expression of nitrotyrosine and FGF-23 (G1, G2 and G3 groups); (B) calcified coronary stained by von Kossa; (C) nitrotyrosine-positive expression in
calcified coronary (G4 and G5 groups); (D) positive FGF-23 expression in calcified coronary in G4 and G5 groups (magnification, 3200).
Fig. 2. FGFR-1 immunohistochemical expression in coronaries and myocardium tissue of the animals studied. (A) Negative control of FGFR-1
(omitting primary antibody); (B) FGFR-1-positive expression in calcified coronary and cardiomyocytes; (C) FGFR-1-positive expression in cardiomyo-
cytes (magnification, 3200).
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Fig. 3. Runx-2 immunohistochemical expression in coronaries and myocardium tissue of the animals. (A) Runx-2-negative expression in G1 and G2
groups (magnification, 3400); (B) Runx-2-positive expression in nucleus from the cells in coronaries and cardiomyocytes in G3, G4 and G5 groups
(magnification, 3400; detail: 31000).
Fig. 4. Analysis of arterial lesions score and a-actin expression of nephrectomized animals. (A) Normal artery (score 0); (B) a calcified artery (score 3);
(C) a normal artery expressing a-actin; (D) a calcified artery expressing low a-actin (magnification, 3580).
Table 3. Analysis of the isolated effects of PTH and phosphorus on structural, biochemical and immunohistochemical parameters of nephrectomized
animalsa
Parameter
PTH Phosphorus
nPTH (n ¼ 16) hPTH (n ¼ 16) P pP (n ¼ 17) rP (n ¼ 15) P
TCP (mmHg) 139.6 6 1.4 146.9 6 2.5 <0.05 145.8 6 1.9 140.3 6 2.3 0.075
HW/100 g 0.33 6 0.01 0.42 6 0.02 <0.0001 0.37 6 0.02 0.38 6 0.02 NS
Ht (%) 41.0 6 0.9 38.1 6 1.0 <0.05 41.1 6 1.0 38.0 6 0.9 <0.05
iCa (mmol/L) 0.90 6 0.08 1.09 6 0.11 NS 1.32 6 0.05 0.63 6 0.05 <0.0001
Phosphorus (mg/dL) 10.1 6 1.7 8.5 6 1.2 NS 5.3 6 0.3 13.9 6 1.4 <0.0001
iPTH (pg/mL) 100.9 6 17.9 301.8 6 40.3 <0.0001 190.7 6 32.7 222.1 6 52.4 NS
FGF-23 (pg/mL) 418.8 6 198.6 695.0 6 115.6 NS 352.8 6 101.9 816.3 6 160.9 <0.05
Coronary lesion score 0.53 6 0.18 2.28 6 0.17 <0.0001 1.52 6 0.30 1.54 6 0.36 NS
Myocyte diameter (lm) 11.03 6 0.46 12.37 6 0.31 <0.05 10.92 6 0.35 12.96 6 0.20 <0.001
Fibrosis (%) 3.19 6 1.14 7.55 6 1.37 <0.05 3.68 6 1.00 6.94 6 1.65 0.065
Angiotensin II (%) 1.12 6 0.22 2.74 6 0.25 <0.0001 2.12 6 0.29 1.83 6 0.38 NS
a-Actin (%) 2.80 6 0.09 1.92 6 0.22 <0.01 2.34 6 0.21 2.38 6 0.24 NS
TGF-b (%) 2.29 6 0.24 3.95 6 0.50 <0.01 2.90 6 0.48 3.49 6 0.54 NS
aData are expressed as mean 6 standard error. hPTH = high parathyroid hormone; Ht = hematocrit; HW/100 g = heart weight/100 g of body weight;
nPTH = normal parathyroid hormone; NS = statistically not significant; PTH = parathyroid hormone.
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We observed a nitrotyrosine expression only in the cor-
onaries of the animals that received hPTH infusion. This
result demonstrated the important role of PTH in increasing
the OS leading to VC.
Our animals developed myocardial hypertrophy with
major participation of the process of fibrosis, and the ani-
mals submitted to hPTH infusion and rP diet showed more
fibrosis than the others. It is known that PTH activates
fibroblasts and regulates pro-fibrotic factors, such as aldos-
terone and angiotensin II [25]. In this study, we could
demonstrate a dependency of angiotensin II expression on
PTH serum level. Certainly, this would be an important factor
on cardiac remodeling. Although the phosphorus-dependent
fibrosis results have not achieved statistical significance,
phosphorus may have also participated in the process of
fibrosis as was demonstrated by Amann et al. [21].
Analyzing some of the proteins involved in cardiac re-
modeling, we found that the TGF-b expression was influ-
enced by PTH levels. It is believed that PTH activates
protein kinase C, which is hypertrophy inducing and in
addition, activates other proteins, such as TGF-b, which, in
turn, stimulates the proliferation of fibroblasts, collagen syn-
thesis and fibrosis [26]. Regarding the angiotensin II expres-
sion in the heart, we could demonstrate a significant increase
in high-PTH groups. It is known that PTH facilitates the
effect of angiotensin II as a mediator of CV lesion [25].
One important finding was PTH as the major determin-
ing factor of coronary artery lesions, ranging from the dis-
continuity of the elastic lamina to the calcification of the
medial layer, confirming the permissive action of PTH as
previously demonstrated by Amann et al. [25]. These re-
sults were not dependent on the concentration of phospho-
rus in the diet, probably because high-PTH concentration
was the strongest determinant of vessel lesion. Uzawa et al.
[27] has previously shown that continuous administration
of PTH at high-flow rates has a catabolic effect on bone,
whereas intermittent PTH administration has an anabolic
effect. Therefore, PTH may have exerted an indirect effect,
increasing calcium and phosphorus load, thus favoring vas-
cular lesion. On the other hand, the animals that received
PTH in physiological concentrations and a rP diet did not
present calcifications.
Another interesting finding was the expression of a-actin,
which correlated negatively with the intensity of the vessels’
lesions. It was shown in literature that as smooth muscle
cells of the vessels suffer phenotypic changes, as occurs in
Fig. 5. Analysis of the isolated effects of PTH on (A) myocyte diameter, (B) fibrosis and TGF-b and angiotensin II expression (C and D, respectively) of
nephrectomized animals.
Fig. 6. Analysis of the isolated effects of phosphorus on (A) FGF-23 serum levels and (B) myocyte diameter of nephrectomized animals.
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hyperphosphatemia, they underexpress a-actin. Wang et al.
[28] confirmed this hypothesis describing the finding of low
a-actin expression in the medial of calcified arteries from
uremic patients. We observed the same finding in the ani-
mals that received high concentration of PTH, unrelated to
phosphorus overload. Therefore, as we described before, the
effect of phosphorus is masked in high PTH concentration
[11].
The animals that received high PTH infusion showed
high FGF-23 expression in calcified coronaries and we
hypothesized that maybe FGF-23 is linked to VC, as pre-
viously demonstrated by Inaba et al. [29]. Trying to verify
if the cells suffered phenotypic modifications, we looked
for the expression of Runx-2. Our results confirmed the
previous observations that phosphorus overload leads to
phenotypic changes in VSMCs. We also showed that high
PTH infusion changes VSMCs phenotype and promotes
coronary calcification [30]. Surprisingly, we also found
Runx-2 expression in cardiomyocytes in the groups with
phosphorus overload (G3 and G5) and high-PTH infusion
(G4 and G5). We believe that both phosphorus and PTH
per se promote modifications in these cells by unknown
mechanisms.
FGF-1 and FGF-2 are involved in biological activities in
adult myocardium and FGFR-1 is the prevalent receptor in
cardiomyocytes [31, 32]. We have shown expression of
FGFR-1 in cardiomyocytes in all groups, but only the
groups with hPTH presented expression of FGFR-1 in cal-
cified coronaries. High concentrations of FGF-23 may in-
duce unspecific Klotho-independent FGFR signaling [33],
justifying our findings of FGF-23 expression in coronaries
in the same groups. Probably, the FGF-23 expression in
coronaries results from the VSMCs that suffered pheno-
typic modification (Runx-2 expression) and also from un-
specific binding to the FGFR-1 [13, 33].
Regarding serum FGF-23 levels, we only observed a
correlation with phosphorus overload. It was previously
shown that FGF-23 is independently associated with ven-
tricular hypertrophy in CKD patients [34] and we could
also hypothesize whether the phosphorus-induced myocar-
dial hypertrophy that was found in our animals was medi-
ated by elevated FGF-23.
Our study suffers the limitation of not evaluating the role
of vitamin D in the cardiac remodeling process, but despite
its importance, our design protocol could not cover all the
involved variables.
Our results point to important aspects regarding the dis-
turbances of the mineral metabolism and CVD in CKD. In
recent years, numerous studies have assessed the participa-
tion of these disturbances in VC, but little attention has
been given to their effect in uremic cardiomyopathy.
We showed that both PTH and phosphorus participated
in hypertrophy and maybe in myocardial fibrosis. How-
ever, the mechanism of action of phosphorus in uremia
was not clear, that is, whether hyperphosphatemia per se
was cardiotoxic or whether it activated inflammatory
pathways, promoting OS and endothelial dysfunction.
As far as we know, our study is unique in the literature
because we analysed all the cardiac remodeling processes
at the same time. In summary, our data confirmed that, in
addition to classical factors already described in uremia,
disturbances of the mineral metabolism, such as phospho-
rus and PTH overload, play an important role in the car-
diac remodeling processes. Nevertheless, further studies
are still necessary to elucidate the molecular pathways of
phosphorus and PTH in the myocardium and coronary
vessels.
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